Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)
Status:
Terminated
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder
both before and after a switch from risperidone to aripiprazole may reveal some of the
cognitive changes that correlate with the improved response, better side effect profile, and
effects on other components of the negative symptom array. Further, examination of brain
functional activity using functional magnetic resonance imaging (fMRI) during a verbal
learning task, as well as behavioral performance and associated electroencephalographic (EEG)
data of episodic memory, working memory and intermediate term verbal memory collected with
the Sustained Attention and Memory Brain Function Test (SAM-BFT), may also provide data
showing the neural correlates of these changes in cognition.
Phase:
N/A
Details
Lead Sponsor:
Louisiana State University Health Sciences Center Shreveport